Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient (Pemb-HT)

University Health Network, Toronto

Status: Active, not recruiting

Conditions: Small Cell Carcinoma, Hypercalcaemic Type; Ovarian Cancer

Treatments: Drug: Pembrolizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT05368207

Pemb-HT

Details and patient eligibility

About

This is a study of pembrolizumab as consolidation therapy for a patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).

Full description

It is an open-label single patient Clinical Trial to be conducted at Princess Margaret Cancer Centre for a patient with Small Cell Carcinoma of Ovary - Hypercalcemic Type (SCCOHT) who has rare and aggressive malignancy with no current consensus on treatment approach and surveillance.

Enrollment: 1 patient

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)

Exclusion criteria

• N/A

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

1 participants in 1 patient group

Pembrolizumab

Experimental group

Description:

Pembrolizumab will be given as an intravenous infusion at 200 mg, every 6 weeks, for 6 cycles.

Treatment:

Drug: Pembrolizumab